Recent developments in Alzheimer's disease therapeutics (Q21245264)

Dimensions Publication ID

Dimensions

18 August 2022

Michael S Rafii

1

Michael S

Rafii

1 reference

Dimensions Publication ID

Dimensions

1032108299

Creative Commons Attribution 2.0 Generic

18 August 2022

language of work or name

English

0 references

publication date

19 February 2009

1 reference

25 April 2019

1 reference

25 April 2019

7

0 references

issue

1

0 references

page(s)

7

0 references

copyright license

1 reference

Europe PubMed Central

on focus list of Wikimedia project

25 April 2019

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

Current state of immunotherapy for Alzheimer's disease

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

beta-Secretase as a therapeutic target for Alzheimer's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

Inhibition and modulation of gamma-secretase for Alzheimer's disease

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2649159

A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease.

27 September 2017

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-7-7

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-7-7

Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-7-7

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-7-7

Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-7-7

Hope in Alzheimer's fight emerges from unexpected places

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-7-7

A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1741-7015-7-7

RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19228370

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1741-7015-7-7

1 reference

Dimensions Publication ID

2038846

1032108299

0 references

Fatcat ID

release_iyug7y6k4bgq7gvkzzhmmrjhla

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iyug7y6k4bgq7gvkzzhmmrjhla

mapped directly with Wikidata item

24 November 2022

based on heuristic

2038846

1 reference

1 reference

1 reference